234 related articles for article (PubMed ID: 19508388)
1. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.
Luetzkendorf J; Mueller LP; Mueller T; Caysa H; Nerger K; Schmoll HJ
J Cell Mol Med; 2010 Sep; 14(9):2292-304. PubMed ID: 19508388
[TBL] [Abstract][Full Text] [Related]
2. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo.
Mueller LP; Luetzkendorf J; Widder M; Nerger K; Caysa H; Mueller T
Cancer Gene Ther; 2011 Apr; 18(4):229-39. PubMed ID: 21037557
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
[TBL] [Abstract][Full Text] [Related]
4. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.
Mohr A; Lyons M; Deedigan L; Harte T; Shaw G; Howard L; Barry F; O'Brien T; Zwacka R
J Cell Mol Med; 2008 Dec; 12(6B):2628-43. PubMed ID: 18373740
[TBL] [Abstract][Full Text] [Related]
7. A therapeutic strategy for metastatic malignant fibrous histiocytoma through mesenchymal stromal cell-mediated TRAIL production.
Lee HJ; Yang HM; Choi YS; Park SH; Moon SH; Lee YS; Sung YC; Kim SJ
Ann Surg; 2013 May; 257(5):952-60. PubMed ID: 23108118
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.
Lathrop MJ; Sage EK; Macura SL; Brooks EM; Cruz F; Bonenfant NR; Sokocevic D; MacPherson MB; Beuschel SL; Dunaway CW; Shukla A; Janes SM; Steele C; Mossman BT; Weiss DJ
Cancer Gene Ther; 2015 Jan; 22(1):44-54. PubMed ID: 25525034
[TBL] [Abstract][Full Text] [Related]
9. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
[TBL] [Abstract][Full Text] [Related]
10. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
[TBL] [Abstract][Full Text] [Related]
11. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
Grisendi G; Bussolari R; Cafarelli L; Petak I; Rasini V; Veronesi E; De Santis G; Spano C; Tagliazzucchi M; Barti-Juhasz H; Scarabelli L; Bambi F; Frassoldati A; Rossi G; Casali C; Morandi U; Horwitz EM; Paolucci P; Conte P; Dominici M
Cancer Res; 2010 May; 70(9):3718-29. PubMed ID: 20388793
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.
Nesterenko I; Wanningen S; Bagci-Onder T; Anderegg M; Shah K
PLoS One; 2012; 7(11):e49219. PubMed ID: 23145127
[TBL] [Abstract][Full Text] [Related]
13. TRAIL-overexpressing Adipose Tissue-derived Mesenchymal Stem Cells Efficiently Inhibit Tumor Growth in an H460 Xenograft Model.
Un Choi Y; Yoon Y; Jung PY; Hwang S; Hong JE; Kim WS; Sohn JH; Rhee KJ; Bae KS; Eom YW
Cancer Genomics Proteomics; 2021; 18(4):569-578. PubMed ID: 34183389
[TBL] [Abstract][Full Text] [Related]
14. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.
Sage EK; Kolluri KK; McNulty K; Lourenco Sda S; Kalber TL; Ordidge KL; Davies D; Gary Lee YC; Giangreco A; Janes SM
Thorax; 2014 Jul; 69(7):638-47. PubMed ID: 24567297
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway.
Yang X; Du J; Xu X; Xu C; Song W
J Immunol Res; 2014; 2014():318098. PubMed ID: 24971369
[TBL] [Abstract][Full Text] [Related]
16. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-expressing gingival-derived mesenchymal stem cells inhibit tumorigenesis of tongue squamous cell carcinoma.
Xia L; Peng R; Leng W; Jia R; Zeng X; Yang X; Fan M
J Dent Res; 2015 Jan; 94(1):219-28. PubMed ID: 25391621
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
[TBL] [Abstract][Full Text] [Related]
20. Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma.
Yulyana Y; Endaya BB; Ng WH; Guo CM; Hui KM; Lam PY; Ho IA
Stem Cells Dev; 2013 Jul; 22(13):1870-82. PubMed ID: 23428290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
